Core Viewpoint - PomDoctor Ltd. is facing a class action lawsuit due to allegations of securities law violations, including misleading statements and undisclosed fraudulent activities [1][3]. Group 1: Class Action Details - The class action is on behalf of investors who purchased PomDoctor securities between October 9, 2025, and December 11, 2025, with a deadline for filing a lead plaintiff motion set for April 6, 2026 [1]. - Investors can contact attorney Lesley F. Portnoy for legal rights discussions and case evaluations [2]. Group 2: Allegations Against PomDoctor - The complaint alleges that PomDoctor was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [3]. - It is claimed that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that the company's public statements omitted critical information regarding false rumors and artificial trading activity [3]. Group 3: Stock Performance Impact - PomDoctor's share price dropped significantly from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, 2025, marking a decline of roughly $0.12 per share or approximately 24% in one trading session [4]. - This decline was attributed to increased volatility and selling pressure amid investor concerns about the company's financial performance and valuation [4].

Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for allegedly engaging in a fraudulent stock promotion scheme that misled investors and artificially inflated its stock price [1][2]. Group 1: Allegations and Investigations - The complaint alleges that Charming Medical failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - Public reports indicate that Charming's stock price surged from an initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news justifying such a spike [3]. Group 2: Trading Suspension - On November 12, 2025, the SEC halted trading of Charming's stock due to the lack of required information from the Company to lift the suspension [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Charming Medical, with options to serve as lead plaintiff or remain an absent class member [4].